Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19170092 | TRIPTOLIDE FORMULATIONS | April 2025 | January 2026 | Allow | 10 | 1 | 1 | No | No |
| 19169843 | USE OF VARENICLINE FOR TREATING OCULAR CONDITIONS | April 2025 | February 2026 | Allow | 10 | 2 | 1 | No | No |
| 18895498 | PHARMACEUTICAL COMPOSITIONS OF CABOTEGRAVIR | September 2024 | September 2025 | Abandon | 12 | 2 | 1 | No | No |
| 18423908 | DRY EYE TREATMENTS | January 2024 | August 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18400069 | PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOF | December 2023 | December 2025 | Allow | 24 | 2 | 0 | No | No |
| 18541570 | INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS | December 2023 | December 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18541995 | LONG-TERM STABLE LIVE FECAL MICROBIOTA COMPOSITION | December 2023 | August 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18503232 | Combination and Uses and Treatments Thereof | November 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18370106 | INTERPENETRATING POLYMER NETWORK HYDROGEL | September 2023 | October 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18236278 | COMPOSITION FOR PREVENTING ADHESION OF AIR-BORNE FINE PARTICLES | August 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18355618 | MODIFIED RELEASE FORMULATION | July 2023 | June 2025 | Abandon | 23 | 4 | 1 | No | No |
| 18255673 | COMPRESSED TABLETS COMPRISING HMO | June 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18144859 | TISSUE ADHESIVE MEMBRANE AND PREPARATION METHOD THEREOF | May 2023 | June 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18307378 | ERODIBLE ANHYDROUS POLYETHYLENE OXIDE FILM | April 2023 | April 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18125562 | COMPOSITIONS AND USE OF VARENICLINE FOR TREATING DRY EYE | March 2023 | January 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18125551 | COMPOSITIONS AND USE OF VARENICLINE FOR TREATING DRY EYE | March 2023 | January 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18125517 | COMPOSITIONS AND USE OF VARENICLINE FOR TREATING DRY EYE | March 2023 | January 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18170634 | Antiviral Resilient Flooring | February 2023 | December 2025 | Abandon | 34 | 0 | 1 | No | No |
| 18019582 | SOLID DOSAGE FORMS OF PALBOCICLIB | February 2023 | December 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18098473 | Biodegradable, Antioxidant, Thermally Responsive Injectable Hydrogel and Uses Therefor | January 2023 | October 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 18095488 | INJECTABLE PREFORMED MACROSCOPIC 3-DIMENSIONAL SCAFFOLDS FOR MINIMALLY INVASIVE ADMINISTRATION | January 2023 | August 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17960002 | ULTRAFINE NANOPARTICLES COMPRISING A FUNCTIONALIZED POLYORGANOSILOXANE MATRIX AND INCLUDING METAL COMPLEXES; METHOD FOR OBTAINING SAME AND USES THEREOF IN MEDICAL IMAGING AND/OR THERAPY | October 2022 | September 2025 | Allow | 35 | 1 | 1 | No | No |
| 17945328 | METHODS OF USING ACTIVIN RECEPTOR TYPE IIB VARIANTS | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17942389 | HEAVY METAL-FREE CALCIUM HYDROXIDE-BASED ACTIVE SUBSTANCE | September 2022 | May 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17900616 | ORAL THIN FILM OF POLYVINYL ALCOHOL AND POLYVINYL ALCOHOL-POLYETHYLENE GLYCOL GRAFT COPOLYMER | August 2022 | February 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 17895681 | METHOD OF PREPARING A THIN FILM COMPOSITE LAYER | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17801440 | SOLID PREPARATION | August 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17890947 | SKIN CARE FORMULATION CONTAINING SILVER NANOPARTICLES | August 2022 | September 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17883982 | POTASSIUM HYDROGEN SALTS OF ALKYLHYDROXAMATES AND COMPOSITIONS COMPRISING THE SAME | August 2022 | February 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17798285 | CD137 BINDING MOLECULES AND USES THEREOF | August 2022 | May 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17796365 | DICLOFENAC SODIUM-CONTAINING ADHESIVE PATCH | July 2022 | September 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17824420 | TISSUE MATRICES WITH CONTROLLED POROSITY OR MECHANICAL PROPERTIES | May 2022 | April 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17748566 | TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | May 2022 | April 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17719529 | COMPOSITIONS AND METHODS FOR DELIVERING DRUGS TO A VESSEL WALL | April 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17708552 | PARTICULATE SUBSTANCES COMPRISING CERAMIC PARTICLES FOR DELIVERY OF BIOMOLECULES | March 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17705627 | NANOFIBROUS MAT CONTAINING CERAMIC PARTICLES WITH RELEASABLE DOPANT | March 2022 | November 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17685732 | Depilatory Compositions Comprising Aminoalkylpropanol | March 2022 | April 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17684219 | INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTS | March 2022 | December 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17591333 | DICLOFENAC SACHET COMPOSITION | February 2022 | June 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17649464 | METHODS AND COMPOSITIONS FOR INHIBITING GLYOXALASE 1 (GLO1) | January 2022 | August 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17583964 | TOPICAL ANTISEPTIC SYSTEM | January 2022 | February 2025 | Allow | 37 | 3 | 0 | No | Yes |
| 17648380 | PREPARATION METHOD OF SUSTAINED-RELEASE MICROPARTICLES | January 2022 | December 2025 | Abandon | 47 | 2 | 1 | Yes | No |
| 17561885 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | December 2021 | April 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17551703 | Foam Formulations Containing at Least One Triterpenoid | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17543505 | COMPOSITIONS AND USE OF VARENICLINE FOR TREATING DRY EYE | December 2021 | December 2023 | Allow | 25 | 1 | 0 | Yes | No |
| 17539188 | Cosmetic Cleansing Powder | November 2021 | June 2025 | Abandon | 42 | 4 | 1 | No | No |
| 17539148 | Powder System For The Care Of Hair | November 2021 | June 2025 | Abandon | 43 | 4 | 1 | No | No |
| 17535000 | BIMATOPROST OCULAR SILICONE INSERTS AND METHODS OF USE THEREOF | November 2021 | December 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17522200 | ORAL THIN FILM | November 2021 | November 2023 | Abandon | 24 | 0 | 0 | No | No |
| 17609525 | NEW FORMULATIONS OF MICROORGANISMS | November 2021 | April 2025 | Abandon | 41 | 2 | 2 | No | No |
| 17609062 | TOPICAL COMPOSITION FOR BALANCING MICROBIOTA OF SKIN | November 2021 | February 2025 | Abandon | 39 | 1 | 2 | No | No |
| 17513966 | POLYMORPHIC MIXTURE OF RIFAXIMIN AND ITS USE FOR THE PREPARATION OF SOLID FORMULATIONS | October 2021 | July 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17501641 | Tamper Resistant Immediate Release Formulations | October 2021 | May 2024 | Allow | 31 | 0 | 1 | Yes | No |
| 17498027 | PROCESS OF REWORKING A CRYSTALLINE FORM OF A GLYCINE TRANSPORT INHIBITOR | October 2021 | December 2024 | Allow | 38 | 1 | 2 | No | No |
| 17467705 | GRAPHENE-BASED MULTIFUNCTIONAL COSMETIC COMPOSITIONS | September 2021 | August 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17409669 | COMPOSITIONS AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES USING AN ORAL DELIVERY SYSTEM | August 2021 | April 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17404128 | MICROSPHERE FORMULATIONS COMPRISING KETAMINE AND METHODS FOR MAKING AND USING THE SAME | August 2021 | December 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17389612 | ORALLY DISINTEGRATING COMPOSITIONS | July 2021 | March 2024 | Allow | 32 | 0 | 2 | Yes | No |
| 17347915 | VISCOELASTIC HYDROGELS WITH FAST STRESS RELAXATION | June 2021 | June 2023 | Allow | 24 | 0 | 0 | Yes | No |
| 17303795 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | June 2021 | March 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17328865 | RADIATION/CHEMOTHERAPY SENSITIZER TO BE USED FOR INTRATUMORAL LOCAL INJECTION AND FOR CONTROLLED RELEASE OF HYDROGEN PEROXIDE WITH HYDROGEL AS CARRIER | May 2021 | June 2024 | Allow | 36 | 2 | 0 | No | No |
| 17230063 | METHODS FOR APPLYING A BIOACTIVE COATING ONTO A SURFACE OF AN IMPLANT | April 2021 | October 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17200454 | TOPICAL FORMULATIONS COMPRISING POLYOXYL LIPID OR FATTY ACID AND POLYALKOXYLATED ALCOHOL, AND USES THEREOF | March 2021 | March 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17275099 | HIGH PERFORMANCE EXCIPIENT COMPRISING CO-PROCESSED MICROCRYSTALLINE CELLULOSE AND SURFACE-REACTED CALCIUM CARBONATE | March 2021 | June 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17267323 | ABUSE DETERRENT PHARMACEUTICAL FORMULATIONS | February 2021 | March 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17169992 | L-PRF MESH REPAIR FOR INGUINAL HERNIA | February 2021 | December 2024 | Abandon | 46 | 1 | 2 | No | No |
| 17158843 | POLYMORPHIC MIXTURE OF RIFAXIMIN AND ITS USE FOR THE PREPARATION OF SOLID FORMULATIONS | January 2021 | March 2023 | Allow | 26 | 1 | 1 | No | No |
| 17159025 | SYSTEMS AND METHODS FOR PRINTING ON A CONTACT LENS | January 2021 | December 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17157047 | STABLE MULTIPARTICULATE PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN | January 2021 | September 2025 | Allow | 56 | 5 | 1 | Yes | Yes |
| 17155128 | COMPOSITION FOR WASHING AND CONDITIONING THE HAIR | January 2021 | February 2025 | Allow | 49 | 3 | 1 | No | No |
| 17261863 | POLYHYDROXYL-CONTAINING POLYMER, PREPARATION METHOD THEREFOR AND USE THEREOF | January 2021 | April 2025 | Abandon | 50 | 2 | 2 | No | No |
| 17260815 | COMPOSITION FOR PREVENTING ADHESION OF AIR-BORNE FINE PARTICLES | January 2021 | November 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17260291 | Process for Preparing Rapidly or Very Rapidly Dissolving Tablets Comprising Freely Soluble API | January 2021 | May 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17253517 | Enzymes Entrapped in Organopolysiloxane Matrix for Treating Intestinal Diseases | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 16973530 | DELAMANID-CONTAINING COMPOSITION | December 2020 | January 2025 | Abandon | 50 | 4 | 0 | Yes | Yes |
| 17104240 | HAIR TREATMENT COMPOSITIONS, KITS, AND METHODS OF USE | November 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17074152 | ANTIOXIDANT COMPLEX AND COMPOSITION FOR FORMING SAME | October 2020 | June 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16948951 | BEVERAGE UNIT AND METHOD TO PROVIDE THE BEVERAGE UNIT | October 2020 | September 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 17044599 | GRANULATION COMPOSITION FORMED FROM CORE PARTICLES, COATING PARTICLES AND A BINDER | October 2020 | September 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 17041635 | LENALIDOMIDE GASTRO-RETENTIVE SUSTAINED-RELEASE TABLET AND PREPARATION METHOD THEREOF | September 2020 | November 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16978693 | PICOLINAMIDES AS FUNGICIDES | September 2020 | October 2024 | Abandon | 49 | 2 | 2 | Yes | No |
| 16983232 | SHEET FOR COVERING WOUND, AND METHOD FOR COVERING WOUND | August 2020 | May 2025 | Abandon | 57 | 4 | 1 | No | No |
| 16932470 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | July 2020 | February 2022 | Abandon | 19 | 1 | 1 | No | No |
| 16918538 | BIMODAL RELEASE ONDANSETRON TABLETS AND METHODS OF TREATING NAUSEA AND VOMITING | July 2020 | September 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16916421 | FORMULATIONS OF RIFAXIMIN AND USES THEREOF | June 2020 | May 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16772273 | NOVEL TERPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS | June 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16898071 | MODIFIED RELEASE FORMULATION FOR (-)-(3AR,4S,7AR)-4-HYDROXY-4-M-TOLYLETHYNYL-OCTAHYDRO-INDOLE-1-CARBOXYLIC ACID METHYL ESTER | June 2020 | February 2026 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16841125 | IMMOBILISING BIOLOGICAL ENTITIES | April 2020 | May 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16753790 | METHOD OF PRODUCTION OF A BRANCHED ORGANOSILICONE POLYMEROUS POLYNUCLEAR ADSORBENT OF HIGH MOLECULAR TOXINS AND THIS ADSORBENT | April 2020 | June 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16833606 | METHODS AND COMPOSITIONS FOR WHITENING TEETH | March 2020 | March 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16830904 | BEVERAGES FOR LOWERING BLOOD PRESSURE | March 2020 | April 2022 | Abandon | 25 | 1 | 1 | Yes | No |
| 16646336 | METHOD FOR PREPARING A SOLID DOSAGE FORM COMPRISING ANTIBODIES BY WET GRANULATION, EXTRUSION AND SPHERONIZATION | March 2020 | May 2025 | Allow | 60 | 2 | 1 | Yes | Yes |
| 16645529 | A Novel Green Micro-Emulsion for Controlling Fungal Wilt Diseases | March 2020 | April 2022 | Abandon | 25 | 0 | 2 | No | No |
| 16797189 | COMPOSITIONS AND METHODS FOR DELIVERING DRUGS TO A VESSEL WALL | February 2020 | December 2021 | Allow | 22 | 2 | 1 | No | No |
| 16640594 | ANHYDROUS ANTIPERSPIRANT AEROSOL COMPOSITION | February 2020 | March 2024 | Allow | 49 | 6 | 1 | Yes | Yes |
| 16637219 | APOPTOSIS-MIMICKING STRUCTURES FOR INDUCING TISSUE REGENERATION | February 2020 | October 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16751521 | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists | January 2020 | August 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16630219 | Method of Increasing Epithelial Permeability Using Nanoparticles | January 2020 | February 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16735009 | Tellurium Nanowires with Anticancer Properties Synthesized by Green Chemistry | January 2020 | December 2023 | Allow | 47 | 2 | 1 | Yes | Yes |
| 16733360 | COMPOSITIONS AND REAGENTS FOR ION BEAM IMAGING | January 2020 | April 2025 | Abandon | 60 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KASSA, TIGABU.
With a 45.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KASSA, TIGABU works in Art Unit 1619 and has examined 760 patent applications in our dataset. With an allowance rate of 34.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner KASSA, TIGABU's allowance rate of 34.7% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KASSA, TIGABU receive 2.93 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KASSA, TIGABU is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +22.6% benefit to allowance rate for applications examined by KASSA, TIGABU. This interview benefit is in the 68% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.7% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.4% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 59.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 44.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.7% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.8% of allowed cases (in the 65% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.